Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
BASKING RIDGE, N.J. and NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc . (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a patient education initiative in partnership with HealthyWomen , the nation’s leading independent, nonprofit health information
BASKING RIDGE, N.J., July 17, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, announced today a program with UpScript, a digital healthcare platform, offering a direct-to-patient telemedicine option for gammaCore™ non-invasive vagus nerve
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
Management to host conference call and webcast at 8:30am ET on Thursday, May 30 BASKING RIDGE, N.J. , May 29, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management and the Board of Directors are making
Data from ACT2 Clinical Trial of gammaCore ® in Cluster Headache Presented for First Time Yesterday During Emerging Science Session Basking Ridge, NJ, April 26, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement,
BASKING RIDGE, N.J. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company has entered into an exclusive contract with Doctor’s Medical, LLC for distribution rights to gammaCore for patients with workers’
Data presented at the 3rd International Brain Stimulation Conference support the use of nVNS for treatment of mild traumatic brain injury and rheumatoid arthritis BASKING RIDGE, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage bioelectronic
Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities Company to host conference call and webcast today, May 14 , at 4:30pm ET BASKING RIDGE, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018 Company to host conference call and webcast today, March 27 , at 4:30pm ET BASKING RIDGE, N.J. , March 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company,
BASKING RIDGE, N.J. , June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive
